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Inflammatory bowel disease (IBD), comprised of Crohn’s disease and ulcerative colitis, is a chronic, relapsing, and remitting 
disease of the gastrointestinal tract whose incidence is rising worldwide, especially in East Asian countries. The etiopatho-
genesis of IBD remains poorly understood. It is currently considered that a combination of genetic and environmental factors 
triggers an aberrant immune response against the commensal intestinal flora in IBD patients. Over the past decades, advances 
in the knowledge of the inflammatory cascade involved in IBD pathogenesis have expanded the pharmacological armamenta-
rium in IBD. Actually, the introduction of specific biological therapies, including anti- tumor necrosis factor, anti-inter-
leukin-12/23, and anti-integrin, has revolutionized the treatment of IBD. Moreover, small molecule agents such as Janus kinase 
inhibitors also now under clinical use. In IBD, a substantial number of patient accompanies various articular manifestations and, 
rheumatic involvement is one of the most common extra-intestinal symptoms. Many of the mechanisms based drugs described 
above have already been used in rheumatic diseases. In addition, some of those drugs can be used to treat both IBD itself and 
accompanied rheumatic involvement, however there are differences in drug usage between these two indications. This review 
aims to briefly review the mechanism-based drug therapies of IBD with particular reference to rheumatic disease. (J Rheum Dis 
2020;27:128-135)
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INTRODUCTION
Inflammatory bowel disease (IBD), comprised of 
Crohn’s disease (CD) and ulcerative colitis (UC), is a 
chronic, relapsing and remitting disease of the gastro-
intestinal tract whose incidence is rising worldwide [1]. 
The etiology of IBD is unknown but is thought to involve 
an interplay between genetic susceptibility, altered gut 
microbiota, and environmental factors that trigger an 
aberrant immune response to commensal bacteria in the 
gut [2]. In CD, inflammation can involve any part of the 
gastrointestinal tract, from the mouth to the anus, and it 
is typically trans-mural and segmental. The most fre-
quently affected sites are the distal ileum and the colon. 
Disease course of CD is often complicated by the develop-
ment of strictures, fistulas, and abscesses that can neces-
sitate surgery [3]. In UC, inflammation begins in the rec-
tum and can extend to the entire colon, and it is typically 
continuous and more superficial, involving only the mu-
cosa and submucosa [4]. Colon cancer is widely acknowl-
edged as a long-term complication of IBD, possibly as a 
result of chronic inflammation. In the active phases, IBD 
patients can manifest diarrhea, abdominal pain, fever, 
rectal bleeding, and weight loss. The disease course is 
highly variable by patients. Being a systemic disease, IBD 
can also be associated with extra-intestinal manifes-
tations, including rheumatological, dermatological, ocu-
lar, or hepatic disorders. Between 6% and 47% of patients 
with IBD suffer at least one extra-intestinal manifestation 
[5]. 
IBD-related arthropathy is one of a group of in-
flammatory arthritides considered as spondyloarthritis 
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(SpA), a group of disorders that also includes ankylosing 
spondylitis, psoriatic arthritis, reactive arthritis, and un-
differentiated SpA. IBD-related SpA is mainly charac-
terized by axial involvement but may also be associated 
with peripheral symptoms, such as synovitis, dactylitis, 
or enthesitis [6]. According to the meta-analysis for the 
prevalence of SpA in IBD, peripheral arthritis, sacroiliitis, 
and ankylosing spondylitis were present in 13, 10, and 3 
percent, respectively [7]. Peripheral arthritis occurs in 
5%∼10% of UC patients and 15%∼20% of those with 
CD. The prevalence of axial involvement is higher in pa-
tients with CD than in UC [8]. Concerning the timing of 
appearance for axial SpA, it can precede IBD symptoms 
from 31% to 50 % of patients. On the other hand, symp-
toms of axial SpA and IBD can co-occur from 15% to 40% 
of patients [9-12]. Ankylosing spondylitis in patients 
with IBD runs a clinical course independent of the IBD 
[13].
Conventional therapeutic options for IBD include 
5-aminosalicylates, corticosteroids, thiopurines, metho-
trexate, which have been used as the initial medications 
in a step-up approach. In recent years, the field has moved 
away from nonspecific immunosuppression towards a 
pathway-based anti-inflammatory approach. Several bio-
logic (antibody) agents and small molecules have become 
available that target specific contributors to the patho-
physiology of IBD, including tumor necrosis factor 
(TNF)-alpha, interleukin (IL)-12/IL-23, alpha4 beta7 
(α4β7) integrin, and Janus kinase (JAK)/signal trans-
ducers and activators of transcription (STAT). In this re-
view, a brief overview of mechanism-based drug therapies 
of IBD with particular reference to rheumatic disease will 
be discussed.
MAIN SUBJECTS
Mechanism-based drug therapies for IBD: 
biologics and small molecule
Multiple studies suggest that IBD results from a dysre-
gulated response by the mucosal immune system to the 
microbiota that resides within the intestinal lumen. This 
dysregulation can be both due to excessive immune re-
activity and to inadequate immune responses to in-
testinal microbiota, highlighting the importance of a bal-
anced immune response. Alterations in intestinal mucus, 
high numbers of bacteria within the mucus, and in-
creased intestinal permeability have been associated with 
IBD [14-17]. Over the past decades, advances in the 
knowledge of the inflammatory cascade involved in IBD 
pathogenesis have expanded the pharmacological ther-
apeutics in IBD. Therapeutic strategies targeting specific 
molecule and inflammatory pathways have emerged as a 
crucial therapeutic strategy in IBD patients who are re-
fractory or relapsing to conventional therapies [18,19]. 
Cytokine blockade 
1) TNF inhibitors
TNF is one of the major proinflammatory cytokines in-
volved in the pathogenesis of IBD. TNF is produced by a 
variety of mucosal cells, mainly macrophages and T cells, 
as a preform on the plasma membrane [20]. The trans-
membrane precursor form TNF (mTNF) is cleaved by the 
converting enzyme into a soluble form (sTNF) [21]. 
There are two forms of TNF receptor, including 55-kDa 
TNFR1 and 75-kDa TNFR2, and both forms are bio-
logically active. Signal transduction of the membrane- 
bound form of TNF can be transmitted through both 
TNFR1 and TNFR2, whereas sTNF mainly signals 
through TNFR1 [22]. The downstream signaling cascade 
of the TNF receptor involves cell proliferation, cytokine 
secretion, or apoptosis [23].
TNF inhibitors are the first biologic agents introduced 
for the treatment of IBD. In 1997, a first controlled study 
showing the efficacy of infliximab in CD patients was re-
ported by Targan et al. [24]. Infliximab is a chimeric mon-
oclonal antibody against TNF-alpha comprised of 75% 
human and 25% murine sequences. The efficacy of in-
fliximab was demonstrated in placebo-controlled trials, 
both CD [25,26] and UC [27] patients who do not re-
spond to conventional therapies. In the past decade, other 
subcutaneous TNF inhibitors have become available. 
Adalimumab, a fully human monoclonal antibody, has 
been shown to induce and maintain remission in moder-
ate-to-severe CD [28,29] and UC [30,31]. Moreover, go-
limumab, a fully human antibody, demonstrated its effi-
cacy inducing and maintaining clinical response and re-
mission in patients with moderate-to-severe UC [32]. 
Usually,  higher dosages are used for IBD patients, and the 
details of drug dosage of these three TNF inhibitors for 
IBD are as follows; 1) infliximab, induction dose: intra-
venous (IV) 5 mg/kg (weeks 0, 2, and 6 weeks), main-
tenance dose: 5 mg/kg every 8 weeks; 2) adalimumab, in-
duction dose: subcutaneous (SC) 160 mg (week 0), 80 mg 
(week 2), maintenance dose: 40 mg every 2 weeks; 3) go-
limumab, induction dose: SC 200 mg (week 0), 100 mg 
(week 2), maintenance dose: 100 mg every 4 weeks. Dose 
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intensification is available when the response is lost for 
infliximab (10 mg/kg every 8 weeks) in CD and adalimu-
mab (40 mg weekly) in CD and UC. 
These three types of anti-TNF agents have also been ap-
proved in adult rheumatic diseases, including rheumatoid 
arthritis, psoriatic arthritis, and ankylosing spondylitis. 
The details of drug dosage for these three TNF inhibitors 
are as follows; 1) Infliximab: rheumatoid arthritis (in 
combination with methotrexate therapy): IV 3 mg/kg at 
0, 2, and 6 weeks, followed by 3 mg/kg every 8 weeks 
thereafter; Psoriatic arthritis (with or without methotrex-
ate): IV 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg 
every 8 weeks thereafter; Ankylosing spondylitis: IV 5 
mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 
weeks thereafter. 2) Adalimumab: Rheumatoid arthritis: 
SC 40 mg every other week (may continue methotrexate, 
other nonbiologic disease-modifying anti-rheumatic 
drugs (DMARDs), corticosteroids, nonsteroidal anti-in-
flammatory drugs (NSAIDs), and/or analgesics); pa-
tients not taking concomitant methotrexate may increase 
the dose to 40 mg every week; Psoriatic arthritis and anky-
losing spondylitis: SC 40 mg every other week (may con-
tinue methotrexate, other nonbiologic DMARDs, corti-
costeroids, NSAIDs and/or analgesics) 3) Golimumab: 
Rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis: IV 2 mg/kg at weeks 0, 4, and then every 8 
weeks thereafter (in combination with methotrexate), SC 
50 mg once a month (in combination with methotrexate). 
Meanwhile, unlike the TNF inhibitors mentioned above, 
which are monoclonal antibody to TNF targeting both 
sTNF and mTNF forms, etanercept, a fully soluble, hu-
man dimeric fusion protein functions as a TNF inhibitor 
by competitively binding to TNF, failed to show efficacy in 
CD [33]. This finding suggests that blocking sTNF alone 
has no therapeutic effect in IBD [34].
2) IL-12/IL-23 blockers
Recent concepts for the pathophysiology of IBD suggest 
a disturbed adaptive immune response, with an excessive 
T helper-1 (Th1) immune reaction, especially in CD. 
IL-12 is the main inducer of Th1 immune responses in 
CD [35] and is produced predominantly by monocytes/ 
macrophages in response to bacterial stimulation [36]. 
Moreover, it has been implicated that the innate immune 
system and the IL-23/T helper-17 (Th17) axis as being 
crucial in the pathogenesis of IBD. Activation of IL-23, 
with its subunits p19 and p40, triggers the differentiation 
of naïve T cells into Th17 cells, which then produce IL-17, 
and IL-21, thereby suppressing regulatory T-cell activity 
[37].
Ustekinumab is a fully human monoclonal antibody that 
blocks the p40 subunit of IL-12/IL-23. Randomized trials 
confirmed the efficacy of ustekinumab inducing re-
mission and maintaining remission in moderate to severe 
CD patients who failed to conventional agents or an-
ti-TNF therapies [38]. Recently, ustekinumab also showed 
efficacy in moderate-to-severe UC patients, and it was ap-
proved for UC [39]. Several other types of a humanized 
monoclonal antibody that selectively targets the p19 sub-
unit of IL-23 are under investigation in IBD [40-42]. The 
details of drug dosage and route of administration for us-
tekinumab are as follows; induction (IV route): ≤55 kg: 
260 mg, 55∼85 kg: 390 mg, ＞85 kg: 520 mg, main-
tenance (SC route): 90 mg every 12 or 8 weeks. On the 
other hand, ustekinumab has also been approved for 
psoriatic arthritis. The details of drug dosage for usteki-
numab are as follows: initial and maintenance: SC 45 mg 
at 0 and 4 weeks, and then every 12 weeks thereafter 
(when used for psoriatic arthritis, may be administered 
alone or in combination with methotrexate). Meanwhile, 
studies evaluating the efficacy of ustekinumab in active 
AS patients were stopped because ustekinumab did not 
achieve key outcome endpoints [43,44].
3) IL-17 blockers
IL-17 induces the recruitment of immune cells to pe-
ripheral tissues, an effect that requires nuclear factor kap-
pa B (NF-kB) activation after IL-17 receptor engagement. 
IL-17 also leads to the induction of many proinflammatory 
factors, including TNF-alpha, IL-6, IL-23, and IL-1b by in-
nate immune cells and antigen-presenting cells [45]. 
Elevated fecal IL-17A levels were described in active CD, 
and IL-17A producing cells within the lamina propria 
were higher in CD than in control group [46]. Meanwhile, 
clinical trials that evaluated secukinumab, a fully human 
anti-IL-17A monoclonal antibody, in CD patients showed 
no efficacy, and, in fact, some patients developed disease 
worsening [47]. Regarding this negative and even para-
doxical response, data have suggested that, in addition to 
proinflammatory activities, IL-17 has essential roles in 
intestinal barrier function, which may have precluded 
clinical efficacy with anti-IL-17 targeted therapies in CD 
[48]. Given the current approved use of secukinumab in 
several rheumatologic diseases, including psoriatic ar-
thritis and ankylosing spondylitis, caution may be needed 
when using it in patients who accompanied by CD. 
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4) IL-6 blockers
IL-6 has multiple proinflammatory effects, and its pro-
duction is upregulated in CD patients [37], accordingly, 
IL-6 targeting therapy was evaluated in IBD. Tocilizumab, 
a humanized monoclonal antibody to IL-6 receptor that is 
now used in rheumatoid arthritis and adult-onset Still 
disease, has been investigated in a randomized pilot trial 
in active CD. In this trial, although tocilizumab demon-
strated a higher clinical response rate compared with pla-
cebo, neither endoscopic nor histological healing was ob-
served [49]. Due to this reason, no further trials of tocili-
zumab in CD were performed. Another fully human mon-
oclonal antibody neutralizing IL-6, PF-04236921, was al-
so evaluated in CD patients who failed anti-TNF therapy 
and showed efficacy in inducing clinical remission [50]. 
However, gastrointestinal abscesses and perforation were 
observed with PF-04236921 treated patients. Although 
most perforations occurred in patients having divertic-
ulitis and previously taking NSAIDs, this adverse event 
may limit a wide spread of IL-6 antagonists and requires 
special attention in future clinical trials.
Anti-trafficking therapies
After activation of the innate and adaptive immune re-
sponse by luminal contents and intestinal microbes, mul-
tiple inflammatory mediators are released and recruit fur-
ther activated immune cells. The maintenance of the con-
stant inflammatory response in the mucosa is supported 
by the migration and homing of activated lymphocytes 
and monocytes into the inflamed mucosa [51]. Leukocytes 
roll along the vascular endothelium and transmigrate 
through the endothelium to the inflamed mucosa. During 
this process, the interaction between cell-expressed in-
tegrins on the surface of leukocytes and tissue-expressed 
adhesion molecules on the vascular endothelium is piv-
otal in attaining the adhesion of a leukocyte to endothelial 
cells [51].
Vedolizumab is a humanized monoclonal antibody that 
blocks the entire α4β7 integrins in the gastrointestinal 
tract. Vedolizumab is not typically associated with sys-
temic effect because it interferes with lymphocyte traf-
ficking limited to the gastrointestinal tract. Vedolizumab 
demonstrated clinical efficacy based on placebo-con-
trolled trials in terms of induction and maintenance 
therapies in both moderate-to-severe UC [52] and CD 
[53]. The details of drug dosage and route of admin-
istration for vedolizumab are as follows; induction (IV 
route): 300 mg (weeks 0, 2, and 6 weeks), maintenance 
(IV route): 300 mg every 8 weeks. Dose intensification 
(300 mg every 4 weeks) is available when the response is 
lost. On the other hands, although natalizumab, a mono-
clonal antibody directed against the α4 subunit, inhibits 
gut and brain lymphocyte migration through blocking 
α 4 β 7 and α 4 β 1 integrin-mediated interactions showed 
efficacy in moderate to severe CD, a serious adverse event 
of progressive multifocal leukoencephalopathy limited its 
use [54,55]. 
Although theoretically, vedolizumab is a drug-specific 
for intestine, thus it will have no or less effect on articular 
manifestations, there have been concerns regarding the 
influence of vedolizumab on articular manifestations in 
patients with IBD-associated SpA yielding controversial 
results. Regarding this issue, several data reported a ben-
eficial effect of vedolizumab use on extra-intestinal mani-
festations such as articular manifestations and SpA 
[56-58]. By contrast, several case series reported new-on-
set or exacerbated arthritis and sacroiliitis in patients 
treated with vedolizumab [59-61]. Currently, it seems 
that vedolizumab at least has no influence on articular 
manifestations in patients with SpA associated with IBD, 
and the onset of rheumatic manifestations may be related 
to the unmasking effect of vedolizumab for latent SpA 
which was quiescent during previous anti-TNF therapy 
[62,63].
Other than anti-integrin therapy, other anti-trafficking 
therapies using sphingosine-1-phosphate receptor mod-
ulators such as ozanimod and etrasimod are under inves-
tigation in UC [64]. Sphingosine-1-phosphate (S1P) is a 
signaling molecule that regulates the traffic of lympho-
cytes out of the lymphoid organs into the bloodstream 
and to inflamed tissue. 
JAK inhibitors
JAKs play a central role in the innate and adaptive im-
mune response. Most cytokines involved in the IBD 
pathogenesis signal through the JAK/STAT pathway. 
Proinflammatory cytokines that signal through the 
JAK/STAT pathway include interleukins IL-2, IL-6, IL-12, 
IL-23, and IFN-gamma; meanwhile, cytokines not using 
the JAK/STAT pathway include TNF, IL-1, IL-8, TGF-β, 
and macrophage colony-stimulating factor [65]. At pres-
ent, four JAKs, including JAK1, JAK2, JAK3, tyrosine kin-
ase 2 (TYK2), as well as seven STATs, that is, STAT1, STAT2, 
STAT3, STAT4, STAT5A, STAT5B, and STAT6 have been 
found in humans. The blockade of the JAK/STAT pathway 
inhibits the activity of multiple cytokines simultaneously, 
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Approved dose in IBD
Indications of 
rheumatic disease
Anti-TNF Infliximab IV CD and UC - Induction: 5 mg/kg (weeks 0, 2, and 6 weeks)
- Maintenance: 5 mg/kg every 8 weeks
   ･ Dose intensification (10 mg/kg every 8 
weeks) is available when the response is 
lost in CD.
RA, AS, PsA, PsO
Adalimumab SC CD, UC, and 
intestinal BD
- Induction: 160 mg (week 0), 80 mg (week 2)
- Maintenance: 40 mg every 2 weeks 
   ･ Dose intensification (40 mg weekly) is 
available when the response is lost in CD, 
UC, and intestinal BD.
RA, AS, PsA, PsO, 
nr-axSpA, UV, HS
Golimumab SC UC - Induction: 200 mg (weeks 0), 
100 mg (week 2)
- Maintenance: 100 mg every 4 weeks
RA, AS, PsA, 
nr-axSpA
Anti-IL-12/23 (p40) Ustekinumab IV
SC
CD and UC - Induction (IV): ≤55 kg: 260 mg 
55∼85 kg: 390 mg
     ＞85 kg: 520 mg
- Maintenance (SC): 90 mg every 12 or 8 weeks
PsA (2nd line), 
PsO (1st line)
Anti-α4β7 integrin Vedolizumab IV CD and UC - Induction: 300 mg (weeks 0, 2, and 6 weeks)
- Maintenance: 300 mg every 8 weeks
   ･ Dose intensification (300 mg every 4 
weeks) is available when the response is 
lost in CD and UC. 
No indication is 
approved
JAK inhibitor Tofacitinib PO UC - Induction: 10 mg bid
- Maintenance: 5∼10 mg bid
RA
IBD: inflammatory bowel disease, TNF: tumor necrosis factor, IL: interleukin, JAK: Janus kinase, IV: intravenous, SC: subcutaneous,
PO: per oral, CD: Crohn’s disease, UC: Ulcerative colitis, BD: Behçet's disease, bid: bis in die, RA: rheumatoid arthritis, AS: 
ankylosing spondylitis, PsA: psoriatic arthritis, PsO: plaque psoriasis, nr-axSpA: Non-radiographic axial spondyloarthritis, UV: 
uveitis, HS: Hidradenitis suppurativa.
and it has been investigated in IBD therapy [66]. 
Tofacitinib is an orally administered pan JAK inhibitor, 
and it potently inhibits JAK1, JAK2, and JAK3 and, to a 
lesser extent, TYK2 [67]. Three-phase III trials with tofa-
citinib confirmed its efficacy in induction and main-
tenance therapy compared to placebo in patients with 
moderately to severe UC [66]. On the other hand, tofaci-
tinib failed in showing efficacy in moderate to severe CD 
patients [68]. Other selective JAK inhibitors, including 
filgotinib (JAK 1 inhibitor), upadacitinib (JAK 1 in-
hibitor), and peficitinib (JAK 3 inhibitor) are under active 
investigations in IBD [69-71]. JAK inhibitors are small 
molecules which differ from other antibody-based bio-
logics in several aspects. Compared with biologic agents, 
small molecules have advantages in terms of lower risk of 
immunogenicity and orally administered medication 
[72]. The details of drug dosage for tofacitinib are as fol-
lows; induction: 10 mg bis in die (bid), maintenance: 5 or 
10 mg bid. Meanwhile, tofacitinib has also been approved 
for use in rheumatoid arthritis. The dosing schedule in 
rheumatoid arthritis is 5 mg twice daily (monotherapy or 
in combination with nonbiologic DMARDs).
Interdisciplinary approach between 
gastroenterologist and rheumatologist
Most biologics and small molecule agents described 
above have already been used in the disease of rheumato-
logic area, as well as IBD. Although the route and fre-
quency of administration are similar between IBD and 
rheumatologic disease, the dosages of the drugs are dif-
ferent between these diseases. In general, drug dosages 
are higher in IBD than in rheumatologic disease when the 
same drug is used; therefore, if the above mentioned sin-
gle drug is used as multiple indications for both IBD and 
rheumatologic disease, it is necessary to confirm drug 
dosage. Indications and dosages of the biologics and 
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small-molecule agents for IBD and rheumatic diseases, 
which are approved in Korea, are summarized in Table 1. 
On the other hand, some rheumatological drugs such as 
secukinumab may exert a negative impact on IBD 
outcomes. Moreover, although not covered in this review, 
NSAIDs, the most commonly used analgesia in rheu-
matic diseases, are relatively contraindicated in patients 
with IBD for concern of disease aggravation. Thus, al-
though safety has not yet been completely established, 
the use of selective cyclooxygenase 2 inhibitors for the 
treatment of rheumatological manifestations of IBD may 
be considered as an alternative to NSAIDs [73]. Considering 
the above-mentioned issues, close partnership between 
rheumatologists and gastroenterologists is needed to 
maximize the therapeutic effect and minimize adverse ef-
fects in the treatment of rheumatic manifestations of IBD. 
CONCLUSION
IBD is increasing worldwide, and the increase is steep, 
especially in East Asian countries. The etiology of IBD is 
still unclear; however, it is presumed to be a combination 
of genetic factors, environmental factors, and abnormal 
immune responses to intestinal microflora. Recent ad-
vances in knowledge for disease mechanism and pharma-
ceutical techniques led to the introduction of more so-
phisticated drugs that target specific molecule and path-
way, and it expended therapeutic options in IBD. A sub-
stantial number of IBD patients accompany extra-
intestinal manifestation, including rheumatologic features. 
In IBD patients having rheumatic involvement, a single 
agent can be used with indications for both IBD and rheu-
matic manifestation. Clinicians are needed to be cautious 
when using a drug for overlapping indication since the ad-
ministration details can be different depending on the 
disease. In addition, some medications used in rheumatic 
disease may precipitate disease exacerbation of IBD. In 
this regard, communication and close collaboration be-
tween gastroenterologists and rheumatologists may be 
highly needed, and it will help to improve the clinical out-
comes of patients.
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